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Summary The prognostic value of cellular DNA content in melanoma metastases was investigated by flow
cytometric analysis of fresh or paraffin-embedded tumour blocks from 95 consecutive patients referred to the
Helsinki University Central Hospital Melanoma Team. Thirty-three per cent of the tumours were DNA
diploid and 67% DNA aneuploid. S-phase fractions were lower in DNA diploid than in DNA aneuploid
tumours (10.7% and 17.6%). Tumour ploidy and S-phase fraction were shown by multivariate Cox model
analysis to be independent prognostic variables and major determinants of survival after first recurrence.
Surprisingly, patients with DNA aneuploid tumours and with tumours with low SPF survived significantly
longer than those with DNA diploid or high SPF tumours. This exceptional finding of favourable prognosis
for DNA aneuploid tumours was more prominent among patients receiving intensive systemic therapy and
among patients with stage IV disease, probably indicating a tendency for DNA aneuploid tumours to have
higher sensitivity to systemic therapy.
Malignant melanoma is known for its varying clinical course
and its resistance to most non-surgical therapeutic app-
roaches. A few parameters such as level of invasion (Clark et
al., 1969) and thickness of tumour (Breslow, 1970) are known
to predict the clinical behaviour of primary melanoma.
Flow cytometric analysis of nuclear DNA content and
S-phase fraction (SPF) is feasible method of estimating the
malignant potential and growth characteristics of various
malignant tumours (Seckinger et al., 1989). In many tumours
DNA aneuploidy and high S-phase fraction (SPF) have been
reported to correlate with poor prognosis. DNA aneuploid
primary melanomas recur earlier than do DNA diploid
melanomas (S0ndergaard et al., 1983; Frankfurt et al., 1984;
Friedlander et al., 1984; Kheir et al., 1988; von Roenn et al.,
1986; Buchner et al., 1985; Lindholm et al., 1989). DNA
aneuploidy has also been associated with shorter survival in
primary melanoma (Lindholm et al., 1989; S0ndergaard et
al., 1983). Patients with DNA aneuploid metastatic melan-
oma have also in one report been found to have a worse
prognosis than patients with DNA diploid tumours (S0nder-
gaard et al., 1983), while in another study there was no
association of DNA ploidy but only of the S-phase fraction
with prognosis (Hansson et al., 1982).
We have correlated the flow cytometrically determined
DNA ploidy and S-phase fraction with the prognosis of
patients with metastatic melanoma. As some of the observa-
tions were unexpected these will be further compared with
similar findings in other malignancies.
Material and methods
Patients
The study population consisted of 95 consecutive patients (58
male, 37 female) with metastatic melanoma treated and
subsequently followed up in the Division of Plastic Surgery
and in the Department of Radiotherapy and Oncology of
Helsinki University Central Hospital between August 1983
and August 1990. The biopsies were taken when a relapse
after primary surgery was suspected. The major characteris-
tics of the patients are presented in Table I.
Follow-up
After the metastatic disease was diagnosed the patients were
routinely followed in either of the above mentioned hospitals
for up to 5 years. The majority of the patients were treated
according to various trial protocols. Systemic chemotherapy
and/or interferon therapy was given to 44 patients, while 51
patients received only local radiotherapy or no therapy in
addition to surgery. The systemic first-line treatments were
sequentially as follows: cisplatin + etoposide (1982-1983),
leucocyte alpha interferon (1984-1988) and interferon +
four-drug chemotherapy from December 1988 onwards. The
time and cause of death were recovered from hospital files
Table I Patient and tumour characteristics
Number of:
specimens examined
patients examined
130
95
Sex
Female 37
Male 58
Age, mean (range) 57 (25-82)
Stage at time of recurrencea
III 48
IV 47
Localisation of first recurrence
Cutaneous or subcutaneous 26
Lymph nodes 58
Liver 4
Lung 8
Bone 1
Brain 2
Other 4
Status at end of study (median follow up time)
Alive 36 (27 months)
Dead 59 (14 months)
Number of patients with specimen available
Fresh histological 76
Fine needle 7
Fresh histological + fine needle 5
Paraffin embedded 7
aIncludingeightpatientswithmetastaticdisease atprimaryadmission
to clinic.
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and from the Central Statistical Office of Finland. Since the
majority ofpatients (n = 55) expired due to metastatic melan-
oma only one from another disease, and three of undefined
causes, only crude survival was used in the survival analysis.
The median survival was 14 months (range 2 to 58 months).
Thirty-six patients were alive at time of the analysis. Their
median follow-up time was 27 months (range 2 to 239
months).
Tumour samples
The study material consisted of 135 microscopically verified
metastases from these 95 melanoma patients. Histological
samples (n = 107) of various tissues supplied by our plastic
surgery team were immediately frozen in solution (40 mM
trinatrium citrate, 250 mM sucrose and 5% DMSO) using
liquid nitrogen and stored thereafter at - 80°C until ana-
lysed. Fine needle aspiration samples (n = 18) were taken by
oncologists and were centrifuged and resuspended in RPMI
with 5% DMSO and frozen in liquid nitrogen until analysed.
Ten samples were paraffin embedded. By histological exam-
ination of the adjacent sections all the specimens were
confirmed to represent melanoma.
Flow cytometric analysis
At the time of analysis the tumour samples were rapidly
thawed in a 37C water bath and processed immediately into
single cell suspensions by scalpels and scissors. This cell
suspension was then filtered through a 50-nm nylon mesh,
and the fitrate was centrifuged for 5 min at 1600 r.p.m.
Chicken and trout red blood cells were added as internal
standards in most of the samples (Vindel0v et al., 1983).
The pellet was resuspended by addition of 0.5 ml of
ethidium bromide (50 Lgml-' in 1OmM Tris buffer, 1 mM
EDTA, 0.3% Nonident P40, pH 7.5). The tube was vortexed
and held on ice for 15 min. Then 0.25 ml of a solution
containing 1 mgml-' RNAase (Sigma) was added to the
tube and incubated for 15 min at room temperature. Immed-
iately before analysis the sample was filtered through a 30Jm
nylon mesh.
Ten samples were prepared from paraffin-embedded mat-
erial according to the procedure described previously (Kouri
et al., 1990).
Routinely 15,000 cells per sample were analysed with an
EPICS C flow cytometer (Coulter, Hialeah, Florida). A 2-W-
argon ion laser was used for excitation at a wavelength of
488 nm, and the total emission above 590 nm was measured.
The mean coefficient of variation of the diploid peak was
5.11 (s.d. 2.27).
The flow cytometric parameters evaluated included the
DNA ploidy and DNA index (DI, where DI represents the
ratio of the aneuploid stem line GI DNA peak channel to
diploid stem line G1-DNA peak channel). Tumours were
classified as aneuploid if there was a second GI-peak in
addition to the diploid GI-peak. Aneuploid tumours with a
DI between 1.9 and 2.1 and a definable S- and G2M-phase
were defined as tetraploid. The S-phase fraction (SPF) was
calculated as described previously (Pyrh6nen et al., 1991).
When multiple samples per patient were available the mean
SPF value was used, and the DNA ploidy of the patient was
coded as the most deviant DNA ploidy among the samples.
Samples with a coefficient of variation greater than 8.0% or
with a large amount of debris or with near diploid aneu-
ploidy were excluded from the cell cycle analysis. Since the
distribution of SPF values differed significantly between
DNA diploid and aneuploid tumours, a new parameter SPF
index was calculated, dividing the SPF values into two
groups based on whether the individual patients' SPF was
over or under the median SPF of his DNA ploidy group.
Statistical methods
Differences between mean values were analysed using Stu-
dent's t-test, and differences between frequencies using the
contingency tables.
For calculation of survival after metastases product limit
survival analysis was performed using the BMDP IL com-
puter program (Dixon, 1988). Brookmeyer-Crawley 95%
confidence limits for median survival time are reported. Cal-
culations of the significance of observed differences were
performed using the log rank test (Mantel-Cox). P-values
under 0.05 were considered significant. Cox multivariate
analysis was performed using DNA ploidy, SPF index, TNM
stage, sex, age and tumour pigmentation as covariates.
Results
Ploidy andS-phasefraction
A single diploid clone was seen in 33 patients, while 43 other
patients had a single aneuploid clone in addition to the
diploid one. A further six patients had a tetraploid clone, and
13 showed multiple aneuploid clones. The proportion of
diploid samples was comparable in fresh histological speci-
mens (37/107), paraffin embedded specimens (7/10) and fine
needle aspirates (7/18).
The S-phase fraction was calculable for 74 patients.
The DNA diploid tumours (n = 31) showed a significantly
(P<0.0002) lower SPF than those which were DNA aneu-
ploid (n = 43) median 10.3 and 15.5, respectively. The mean
SPF of fresh histological specimens was essentially equal to
that of paraffin embedded material and fine needle aspirates,
14.4, 15.4 and 14.1, respectively.
Survival afterfirst recurrence
Patients with DNA diploid tumours had a worse prognosis
(median survival 16 months) after the first recurrence than
did patients with DNA aneuploid tumours (median survival
28 months) (Figure 1, Table II). This difference was even
more prominent among patients receiving systemic therapy
and patients with stage IV disease (Table II).
The S-phase fraction alone was not a significant prognostic
factor since the aneuploid tumours had significantly higher
SPF but more favourable prognosis. When the imbalance
between different DNA ploidies' SPF was controlled for by
adjusting the individual SPF with respect to the median SPF
of each respective DNA ploidy group SPF index was also a
highly significant prognostic factor (Figure 2). SPF above the
median was the most important determinant of poor prog-
nosis in Cox's multivariate analysis (P<0.002), followed by
TNM stage IV and DNA diploidy (P<0.05), when age, sex
and tumour pigmentation were analysed as covariates.
Table II summarises the correlation of survival analysis
and flow cytometric parameters as well as some clinical and
histological parameters.
Years
At risk
DNA aneuploid 43 27 15
DNA diploid 17 10 5
Figure 1 Cumulative proportion of melanoma patients surviving
after appearance of first metastases. Patients with DNA aneu-
ploid tumours (-*-, n = 62) have better survival than those
with DNA diploid tumours (-O-, n = 33), P = 0.065, product
limit, Mantel-Cox.MELANOMA DNA FLOW CYTOMETRY 751
Table II Relationship of DNA flow cytometric and clinical parameters to survival
afterfirstmelanomametastasesusingBrookmeyer-Crawley 95% confidencelimitsfor
median survival and product limit Mantel-Cox test for survival analysis
Median 95% Observedl
n survival Confidence expected X2 p
DNA ploidy
diploid 33 16 12-25 0.77
aneuploid 43 29 22- 1.38
multiploid 13 25 16-36 1.06
tetraploid 6 32 24-32 0.92 3.96 0.27
DNA ploidy
diploid 33 16 12-25 0.85
aneuploid 62 28 23-38 1.38 3.39 0.07
DNA ploidy and treatment
treat-diploid 21 16 12-25 0.80
treat-aneuploid 31 32 24-40 1.87 5.68 0.02
notreat-diploid 12 16 6- 0.90
notreat-aneuploid 31 28 14-36 1.17 0.48 0.49
Stratified over treatment 4.28 0.04
DNA ploidy and stage
III-diploid 19 25 16- 0.94
III-aneuploid 29 27 24-38 1.12 0.20 0.65
IV-diploid 14 11 4-12 0.76
IV-aneuploid 33 28 12- 1.84 6.51 0.01
Stratified over stage 4.36 0.04
S-phase fraction
< 12.5 37 25 16-32 1.03
> 12.5 37 26 13-38 0.97 0.05 0.83
SPF index
< Median 38 38 25- 0.66
>Median 36 16 11-25 1.66 9.59 0.002
Sex
male 58 26 19-38 0.90
female 37 23 12-28 1.21 1.28 0.26
Age
<57 47 29 22-44 0.82
> 57 48 19 13-26 1.28 3.14 0.08
Stage
III 48 26 23-36 0.83
IV 47 14 11-32 1.21 2.18 0.14
3 Years
Below median 28 21 13
Above median 17 10 3
Figure 2 Cumulative proportion ofmelanoma patients surviving
after appearance of first metastases. Patients with SPF below or
at the median ( * , n = 38) have significantly better prognosis
than patients with SPF above the median (-O-, n = 36).
P = 0.002, product limit, Mantel-Cox.
Discussion
In the present study of the prognostic value of DNA ploidy
and S-phase fraction in 95 metastatic melanoma patients,
DNA aneuploidy and low S-phase fraction were observed to
predict longer survival after the first metastases have ap-
peared. The observation of DNA aneuploidy as a favourable
feature is in contrast to the earlier report on metastatic
melanoma (S0ndergaard et al., 1983) and conflicts with those
concerning primary melanomas (Frankfurt et al., 1984;
Buchner et al., 1985; Hansson et al., 1982; Sondergaard et
al., 1983). Our data confirm the previous report by Hansson
et al. (1982) on poor prognosis of metastatic melanoma
patients with high SPF.
In many solid tumours some disagreement exists on the
prognostic value of DNA ploidy (Kouri et al., 1990; Kal-
lioniemi, 1988; Volm et al., 1985; Zimmerman et al., 1987;
Tirindelli-Danesi et al., 1987; Look et al., 1984). Frequently,
DNA aneuploid tumours have more readily been associated
with unfavourable prognosis than have DNA diploid tu-
mours. This has not, however, been a consistent finding. In
some cases, no difference in prognosis between DNA diploid
and aneuploid tumours has been observed (Kallioniemi,
1988) or the opposite result (of DNA aneuploidy being a
favourable sign) has been reported (Goldsmith et al., 1986).
The systemic treatment given to the patients varied sequen-
tially during the study period. At the early years of the study
cis-platinum + etoposide was used as first line treatment,
later substituted by interferon alfa and most recently by
a four-drug chemotherapy in combination with interferon
(manuscript under preparation). Principally all the patients
with inoperable tumours and eligible to aforementioned pro-
tocols were treated with systemic therapy. No adjuvant treat-
ment was used for those receiving radical operations. DNA
aneuploidy correlated with favourable prognosis only among
patients receiving systemic therapy. Since the patients were
given systemic therapy irrespective of DNA ploidy, this may
indirectly indicate a better response to therapy of DNA
aneuploid tumours. Anyhow, although the decision to treat a
patient systemically was not based on flow cytometric para-
meters, the other prognostic factors are not necessarily
balanced in the two treatment groups. DNA aneuploid neur-
oblastomas (Look et al., 1984) have been reported to be
more sensitive to chemotherapy than DNA diploid ones.
Also regarding microcellular lung carcinoma near- diploid
type tumours might be more resistant to chemotherapy than
are hyperdiploid tumours (Abe et al., 1987). Interestingly,
similar phenomenon to these have been observed in radiosen-752 T. MUHONEN et al.
sitivity of other malignancies: DNA aneuploid laryngeal car-
cinomas (Goldsmith et al., 1986), carcinomas of the oral
cavities (Franzen et al., 1987) and the uterine cervix (Dyson
et al., 1987), as well as bladder carcinomas (Jacobsen et al.,
1987) have been reported as more radiosensitive than DNA
diploid tumours. This probably has been contributed to a
better prognosis for patients with DNA aneuploid tumours
after curative radiotherapy in these tumour groups (Gold-
smith et al., 1986; Franzen et al., 1987). On the other hand,
in most of the studies concerning tumours treated primarily
by surgery, such as breast cancer and colorectal malignan-
cies, DNA aneuploidy indicates a less favourable prognosis
(Kallioniemi, 1988). In malignant melanomas the significance
of DNA ploidy in different treatment modalities is unknown,
and cannot yet be estimated in this study due to our limited
number of patients.
Like the DNA ploidy pattern, SPF has been described as
having prognostic value for solid tumours (Kallioniemi,
1988). In the present study, low SPF was observed to be an
indicator of a good prognosis. Patients with SPF at or below
median SPF had a median survival twice as long as did those
with high SPF. The observation is in harmony with earlier
reports on melanomas (Hansson et al., 1982) and many other
malignancies (Kallioniemi, 1988).
It remains to be determined whether flow cytometric para-
meters may be used as a guideline for selecting a treatment
strategy for each patient. Further expansion of this study and
a detailed analysis of patients receiving chemotherapy or a
new highly promising combination of chemotherapy plus
interferon (manuscript under preparation) will hopefully pro-
vide more information in this respect.
The flow cytometric method is rapid and practicable for
analysing certain biologic features of human tumours, such
as DNA ploidy pattern and proliferation characteristics. We
found that, in contrast to earlier findings in primary melan-
oma, DNA aneuploidy in metastatic melanoma is an indi-
cator of favourable prognosis especially among patients
receiving systemic therapy. The favourable prognosis of
patients with low SPF was also demonstrated. We thus con-
clude that flow cytometric data may contribute to the
difficult task of selecting patients for various treatment or
follow-up protocols.
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